ADMA Biologics, Inc. is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases. It produces and markets three FDA-approved plasma-derived biologics: BIVIGAM for primary humoral immunodeficiency (PI), ASCENIV for PI, and NABI-HB for enhanced immunity against hepatitis B. Additionally, through its ADMA BioCenters subsidiary, the company operates as an FDA-approved plasma collector in the U.S., supplying blood plasma for its products. We show 50 historical shares outstanding datapoints in our coverage of ADMA's shares outstanding history.
Understanding the changing numbers of ADMA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADMA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADMA by allowing them to research ADMA shares outstanding history
as well as any other stock in our coverage universe. |
Free ADMA Email Alerts:
Video: Shares Outstanding Importance
